Too Much Cysteine Comes at a Cost: Surplus Amino Acid Triggers Deadly Iron Overload in Cells

Cysteine has long been celebrated as one of the workhorse molecules of the cell. It anchors disulfide bonds that hold proteins in shape, feeds the iron-sulfur clusters that power respiration, and supplies the backbone of glutathione, the cell’s most abundant antioxidant. When free cysteine runs low, cells become vulnerable to oxidative assault, and when the amino acid is depleted entirely, a form of regulated necrosis called ferroptosis can follow. A new study now upends the assumption that more of this amino acid is always better. Writing in Nature Metabolism, Nakamura and colleagues demonstrate that an overabundance of free, unconjugated cysteine is itself toxic, disrupting the delicate handling of iron inside mitochondria and triggering a distinct iron-dependent form of cell death. The findings reveal why cells invest so heavily in sweeping free cysteine out of the cytosol and locking it into glutathione.

The research team set out to test what happens when intracellular cysteine levels rise beyond the capacity of normal metabolic routing. Free cysteine is chemically reactive: its thiol side chain readily undergoes oxidation, participates in redox cycling, and can generate downstream metabolites such as hydrogen sulfide and thiosulfate. Cells therefore keep free cysteine concentrations tightly buffered, primarily by channeling the amino acid through two routes: incorporation into the tripeptide glutathione via the actions of glutamate-cysteine ligase and glutathione synthetase, and catabolism through the transsulfuration pathway. The new work shows that when these routes are overwhelmed or bypassed, the excess free thiol does not sit idly by. Instead, it interferes with one of the most carefully choreographed processes in the cell: mitochondrial iron management.

Iron is a double-edged element in biology. It is indispensable as a cofactor in hemoglobin, cytochromes, iron-sulfur proteins, and catalases, yet in its ferrous form it catalyzes the Fenton reaction, converting hydrogen peroxide into the hydroxyl radical, one of the most destructive reactive oxygen species known. Cells must therefore import iron when needed, store it in ferritin when surplus, and export it when overloaded. Mitochondria sit at the center of this economy because they consume the bulk of cellular iron for the assembly of heme and iron-sulfur clusters. The study by Nakamura and colleagues shows that excess free cysteine destabilizes this economy, causing iron to accumulate in mitochondria in a labile, redox-active pool rather than being safely sequestered into functional cofactors.

Using a combination of genetic, pharmacological, and imaging approaches, the researchers tracked the consequences of cysteine overload in cultured cells and in vivo models. They found that elevated free cysteine led to mitochondrial iron loading, collapse of mitochondrial membrane potential, lipid peroxidation, and ultimately cell death. Importantly, the lethality was suppressed by iron chelators, positioning the death process squarely in the iron-dependent category alongside ferroptosis. Yet the mechanism appeared distinct from classical ferroptosis, the iron-driven lipid peroxidation death program first characterized by Dixon and colleagues in 2012. Classical ferroptosis depends on the failure of the glutathione peroxidase 4 axis, leaving peroxidized phospholipids unrepaired. The cysteine-overload death described here instead arises from direct perturbation of mitochondrial iron homeostasis by the free amino acid itself, an upstream insult that the authors delineate from the canonical downstream peroxide-removal failure.

The mechanistic details emerging from the study illuminate why the thiol is so disruptive. Free cysteine can chelate and reduce iron, keeping it in the ferrous state and mobilizing it into labile pools. In mitochondria, where respiratory complexes continuously generate superoxide and hydrogen peroxide as by-products, a flood of redox-active ferrous iron creates a perfect storm for radical generation. The authors observed that mitochondrial iron-sulfur cluster biogenesis and storage capacity were strained by the surplus, and that the resulting accumulation of labile iron sensitized membranes to peroxidation. Experiments modulating the transsulfuration enzyme cystathionine gamma-lyase and the cystine-glutamate antiporter system xCT reinforced the picture: rerouting cysteine away from the free pool protected cells, whereas blocking its incorporation into glutathione accelerated iron loading and death.

These results reframe a long-standing metabolic puzzle. Researchers have repeatedly noted that interventions to raise intracellular cysteine, whether through supplementation of N-acetylcysteine precursors, inhibition of cysteine catabolism, or genetic manipulation of transporters, can produce unexpectedly complex effects, sometimes protective and sometimes harmful. The new work provides a unifying explanation: the benefit or harm depends on where the cysteine ends up. Cysteine safely packaged inside glutathione is an antioxidant asset. Free cysteine lingering in the cytosol and mitochondria is a liability that chemically subverts iron handling. The study therefore explains the evolutionary logic of the cell’s aggressive routing of cysteine into glutathione synthesis, a pathway whose flux rivals that of many core metabolic reactions.

The findings carry substantial implications for cancer metabolism, one of the most active frontiers in cysteine biology. Many tumors upregulate system xCT to scavenge cystine from the tumor microenvironment, buffering themselves against oxidative stress and therapy-induced ferroptosis. Drugs that block cystine import are in clinical development precisely because cysteine starvation is thought to render cancer cells fragile. But the new study suggests a subtler landscape: tumor cells must not only import cysteine but also dispose of it rapidly into glutathione. Cancer cells with constrained glutathione synthesis capacity or impaired transsulfuration may find that high cysteine uptake becomes a metabolic trap, loading their mitochondria with redox-active iron and making them vulnerable to iron-dependent death. Conversely, therapies that deliver excessive cysteine could, under some biochemical conditions, backfire by feeding the very pool that triggers toxicity.

Beyond oncology, the work resonates with disorders of iron metabolism and mitochondria. Conditions characterized by mitochondrial iron overload, including certain sideroblastic anemias and Friedreich’s ataxia, involve the misdirection of iron into labile mitochondrial deposits that fuel oxidative damage. The discovery that a simple amino acid can drive this pathology opens the possibility that perturbations of sulfur amino acid metabolism contribute to such diseases, or conversely, that manipulating cysteine disposition could ameliorate them. Neurodegenerative contexts, where both cysteine dysregulation and mitochondrial iron accumulation have been reported, merit renewed scrutiny through this mechanistic lens. The study also invites a reassessment of high-dose thiol supplementation strategies, which are widely used in preclinical research and occasionally in clinical practice, by highlighting a dose- and compartment-dependent tipping point at which antioxidant chemistry turns into pro-oxidant catastrophe.

Technically, the study exemplifies the modern metabolic toolkit. The authors combined targeted metabolomics to quantify cysteine pools, organelle-targeted fluorescent and genetically encoded sensors to track labile iron in mitochondria, lipid peroxidation probes to monitor ferroptotic damage, and rescue experiments with iron chelators, ferroptosis inhibitors, and pathway-specific enzyme modulators to disentangle causal chains. This layered approach allowed the team to distinguish the cysteine-overload death program from necroptosis, apoptosis, and canonical ferroptosis, and to place the primary lesion at the interface of cysteine chemistry and mitochondrial iron metabolism. The depth of mechanistic resolution provides a template for future studies of metabolite toxicity, an area in which the field has often been content to correlate metabolite abundance with cell fate without pinning down the responsible chemistry.

What emerges is a compelling biological lesson: in metabolism, as in economics, there is no free lunch, and free cysteine is no exception. The cell’s insistence on converting cysteine into glutathione at remarkable speed is not a quirk of chemistry but a survival imperative. Nakamura and colleagues have shown that when that imperative is violated, iron turns against the mitochondria that depend on it, and the cell pays the ultimate price. As the fields of ferroptosis, mitochondrial biology, and cancer metabolism converge on the cysteine-iron axis, this study is likely to shape therapeutic thinking for years to come, reminding researchers that the intracellular destination of a nutrient can matter far more than its abundance.

Subject of Research: How excess free cysteine disrupts mitochondrial iron homeostasis and drives a distinct iron-dependent form of cell death.

Article Title: The high price of ‘free’ cysteine

Article References: Cheah, M., & Ubellacker, J. M. (2026). The high price of ‘free’ cysteine. Nature Metabolism. https://doi.org/10.1038/s42255-026-01620-x

Image Credits: AI Generated

DOI: 10.1038/s42255-026-01620-x

Keywords: cysteine, mitochondria, iron homeostasis, ferroptosis, glutathione, cell death, metabolism, cancer metabolism, lipid peroxidation, oxidative stress, iron-sulfur clusters, transsulfuration pathway